Identification of Proteomic Subtypes with Differential Responses to Immune Checkpoint Inhibition in Cutaneous Melanoma
PURPOSE: Predictive biomarkers for combined PD-1/CTLA-4 blockade in metastatic melanoma remain limited. We analyzed pretreatment proteogenomic data to define response and resistance biology. EXPERIMENTAL DESIGN: We profiled 208 pretreatment FFPE specimens from patients with metastatic cutaneous melanoma treated across 12 institutions, including 164 receiving dual PD-1+CTLA-4 blockade (Discovery, n=97; Validation 1, n=67) and 44 receiving PD-1 monotherapy. Tumors underwent TMT-based proteomics, RNA sequencing, and targeted/low-pass whole-genome sequencing. Pathway clustering, survival modeling, deconvolution, and machine-learning classification defined and validated subtype signatures. RESULTS: Proteomic pathway clustering identified three reproducible ICI subtypes: immune-enriched ICI-sensitive, ribosome-high, and EMT-like/stromal-enriched. Subtypes stratified progression-free survival after dual ICI in the Discovery (P=0.01) and Validation 1 cohorts (P=0.02). The ICI-sensitive subtype had the highest responder fraction (74% and 73%), compared with ribosome-high (67% and 60%) and EMT-like tumors (44% and 43%) in the Discovery and Validation 1 cohorts, respectively. Subtype-outcome associations were consistent with previous immunotherapy datasets, with pooled hazard ratios ≈0.5-0.8 for immune-enriched tumors. Subtypes plus clinical variables predicted 3-year progression/death better than clinical variables alone in Validation 1 (AUC 0.80 vs 0.64). A 127-protein classifier recapitulated subtype membership in Validation 1 (AUC 0.89-0.97) and predicted 3-year progression/death with AUC 0.79. Subtypes reflected distinct immune, translational, and stromal/ECM programs and nominated POLR3A-associated biology as a candidate resistance axis. CONCLUSIONS: Proteomic pathway states define reproducible, biologically interpretable melanoma subtypes associated with differential benefit from dual PD-1/CTLA-4 blockade. A clinically tractable 127-protein classifier provides a foundation for prospective biomarker-driven combination immunotherapy trials.
Authors
- Charlotte Eielson Ariyan (ORCID: https://orcid.org/0000-0003-0818-3895)
- Mario Sznol (ORCID: https://orcid.org/0000-0003-4137-9662)
- John M. Kirkwood (ORCID: https://orcid.org/0000-0002-3570-4476)
- Ryan Joseph Sullivan (ORCID: https://orcid.org/0000-0001-5344-6645)
- Genevieve Marie Boland (ORCID: https://orcid.org/0000-0002-7522-6173)
- Tara C. Mitchell (ORCID: https://orcid.org/0000-0002-8186-7284)
- Rose C. Pletcher (ORCID: https://orcid.org/0009-0006-0244-0570)
- Ata S. Moshiri (ORCID: https://orcid.org/0000-0001-6684-4503)
- Amanda G. Paulovich (ORCID: https://orcid.org/0000-0001-6532-6499)
- Douglas Buckner Johnson (ORCID: https://orcid.org/0000-0002-6390-773X)
- Diwakar Davar (ORCID: https://orcid.org/0000-0002-7846-8055)
- Jacob J. Kennedy (ORCID: https://orcid.org/0000-0003-2532-3861)
- Richard G. Ivey (ORCID: https://orcid.org/0000-0001-8218-7718)
- Dirk Schadendorf (ORCID: https://orcid.org/0000-0003-3524-7858)
- Giorgos Constantine Karakousis (ORCID: https://orcid.org/0000-0002-9321-2795)
- Azra Krek (ORCID: https://orcid.org/0009-0001-7845-9984)
- Mehdi Mesri (ORCID: https://orcid.org/0000-0001-7295-9673)
- Paul W. Harms (ORCID: https://orcid.org/0000-0002-0802-2883)
- Jianhui Gong (ORCID: https://orcid.org/0000-0002-3910-9260)
- Shrabanti Chowdhury (ORCID: https://orcid.org/0000-0001-8429-7822)
- Anna Malgorzata Czarnecka (ORCID: https://orcid.org/0000-0002-2107-3810)
- Alexander J. Lazar (ORCID: https://orcid.org/0000-0002-6395-4499)
- Marcin P. Cieslik (ORCID: https://orcid.org/0000-0002-5467-1040)
- Jedd D. Wolchok (ORCID: https://orcid.org/0000-0001-6718-2222)
- Anna Szumera‐Ciećkiewicz (ORCID: https://orcid.org/0000-0001-5028-3422)
- Yan Chak Li (ORCID: https://orcid.org/0000-0001-6554-5958)
- Ruth Halaban (ORCID: https://orcid.org/0000-0001-8451-1964)
- Anne Zaremba (ORCID: https://orcid.org/0000-0002-6932-0489)
- Georgina Venetia Long (ORCID: https://orcid.org/0000-0001-8894-3545)
- Jeffrey R. Whiteaker (ORCID: https://orcid.org/0000-0001-5042-8580)
- Piotr Lukasz Rutkowski (ORCID: https://orcid.org/0000-0002-8920-5429)
- Marcus Bosenberg (ORCID: https://orcid.org/0000-0003-0166-1612)
- Kourosh Abdollahi (ORCID: https://orcid.org/0009-0005-6010-9694)
- Francesca Petralia (ORCID: https://orcid.org/0000-0001-5096-9854)
- Iman Osman (ORCID: https://orcid.org/0000-0002-1472-1971)
- Zachary T. Herbert (ORCID: https://orcid.org/0000-0001-9401-2464)
- Jeffrey E. Gershenwald (ORCID: https://orcid.org/0000-0003-4519-5369)
- Richard A. Scolyer (ORCID: https://orcid.org/0000-0002-8991-0013)
- Victor Gerardo Prieto (ORCID: https://orcid.org/0000-0001-9204-7161)
- Travis D. Lorentzen (ORCID: https://orcid.org/0000-0002-7941-0250)
- Antonella Bacchiocchi (ORCID: https://orcid.org/0009-0007-3016-2528)
- Tao Liu (ORCID: https://orcid.org/0000-0001-9529-6550)
- Pei Wang (ORCID: https://orcid.org/0000-0002-6890-6453)
- Weiping Ma (ORCID: https://orcid.org/0000-0003-3786-7460)
- Yi Hsiao (ORCID: https://orcid.org/0000-0002-9435-0305)
- Kelly L. Harms (ORCID: https://orcid.org/0000-0002-1502-7914)
- Anna Xing (ORCID: https://orcid.org/0009-0008-3487-4888)
- Nicole Tignor (ORCID: https://orcid.org/0000-0002-5470-3866)
Institutions
- Cape Town HVTN Immunology Laboratory / Hutchinson Centre Research Institute of South Africa (ZA)
- Memorial Sloan Kettering Cancer Center (US)
- The University of Texas MD Anderson Cancer Center (US)
- Pacific Northwest National Laboratory (US)
- Cornell University (US)
- University of Michigan (US)
- Yale University (US)
- California University of Pennsylvania (US)
- Massachusetts General Hospital (US)
- Fred Hutch Cancer Center (US)
- University of Michigan–Flint (US)
- Michigan Medicine (US)
- Dana-Farber Cancer Institute (US)
- Yale New Haven Health System (US)
- Melanoma Institute Australia (AU)
- Essen University Hospital (DE)
- National Institute of Oncology (HU)
- National Cancer Institute (MY)
- University of Pittsburgh Medical Center (US)
- National Cancer Institute (US)
- Center for Cancer Research (US)
- The Maria Sklodowska-Curie National Research Institute of Oncology (PL)
- Weill Cornell Medicine (US)
- New York University (US)
- University of Pennsylvania (US)
- Vanderbilt University Medical Center (US)
- Philadelphia University (US)
- Icahn School of Medicine at Mount Sinai (US)
Publication Details
- Journal
- Clinical Cancer Research
- Published
- 2026-11-17
- DOI
- https://doi.org/10.1158/1078-0432.ccr-26-2295
- Primary Topic
- Cancer Immunotherapy and Biomarkers
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Bristol-Myers Squibb
- Melanoma Research Alliance
- Fred Hutchinson Cancer Research Center
- University of Washington
- Tizona Therapeutics
- National Institutes of Health
- University of Texas MD Anderson Cancer Center
- National Health and Medical Research Council
- National Cancer Institute
- Office of Research Infrastructure Programs, National Institutes of Health